Global cannabinoid reach Elixinol operates with a global distribution footprint across North and South America, Europe, Asia and the Pacific, presenting opportunities to team with regional distributors, retailers and e-commerce platforms to expand market presence and accelerate new product placement.

Publicly traded credibility As a subsidiary of EXL publicly traded on ASX and OTC, there is enhanced credibility and potential for co-marketing, investor-backed partnerships, and joint ventures that can unlock distribution deals and retail shelf presence.

R&D driven portfolio With over 25 years in hemp and a five-year focus on science and R&D of cannabinoid products, there is strong opportunity to position higher-margin, evidence-backed SKUs, white-label or private-label partnerships, and co-development with wellness brands seeking validated formulations.

Earnings and coverage cues Recent earnings transcripts and strategic updates highlight new national distribution agreements and capital structure resets, signaling readiness for expanded channel partnerships, wholesale deals, and sales acceleration through broker/dealer networks and regional distributors.

Regulatory and safety credibility Independent safety studies and ongoing regulatory communications bolster trust with retailers and healthcare-focused channels, enabling entry into pharmacy, wellness clinics, and dietary supplement retailers that require substantiated safety data.